
Related
Related Companies
NSE
BSE
Hyderabad-based Gland Pharma is set to launch its maiden initial public offer on November 9 to raise about Rs 6,500 crore. The price band for the offer has been fixed at Rs 1,490-1,500 per share. The issue will close on 11 November.
The Gland Pharma IPO, India’s largest IPO in the pharmaceutical sector, comprises a fresh issue aggregating up to Rs 1,250 crore and an offer for sale of up to 3.49 crore shares. While China's Fosun Pharma Industrial Pte is offering to sell 1.9 crore equity shares, Gland Celsus Bio Chemicals is planning to sell 1 crore shares. The other two shareholders Empower Discretionary Trust and Nilay Discretionary Trust are offloading 35.73 lakhs and 18.45 lakhs shares, respectively.
The company plans to utilise the fresh issue proceeds for funding incremental working capital requirements, capital expenditure requirements and for general corporate purposes.
The previous largest IPO in pharma space was Rs 1,741 crore raised by Eris Lifesciences in 2017 while Alkem Laboratories and Laurus Labs raised about Rs 1,350 crore each in 2015 and 2016, respectively. So far in India, only 14 companies have raised over Rs 6,000 crore through IPOs.
The company which filed its draft papers in July received capital markets regulator Sebi's go-ahead last week.
Fosun Singapore which is a subsidiary of Shanghai Fosun Pharma holds 74% stake in the company. Other investors of the company include Gland Celsus which owns 12.97% while Empower Trust and Nilay Trust own 5.08% and 2.42% stake respectively.
Kotak Mahindra Capital Company, Citigroup, Haitong Securities and Nomura Financial Advisory and Securities are the book running lead managers to the IPO.
The Hyderabad based pharma company has reported Rs 2,772 crore revenue for the year ended March 2020 as against Rs 2,129.7 crore in the previous year. In 2019-20, it reported a profit of Rs 772.8 crore against a profit of Rs 451.8 crore in the previous fiscal.
So far in 2020, 11 companies have raised Rs 18,484 crore through IPOs of which SBI Cards and Payment Services alone has raised Rs 10,350 crore.
The Gland Pharma IPO, India’s largest IPO in the pharmaceutical sector, comprises a fresh issue aggregating up to Rs 1,250 crore and an offer for sale of up to 3.49 crore shares. While China's Fosun Pharma Industrial Pte is offering to sell 1.9 crore equity shares, Gland Celsus Bio Chemicals is planning to sell 1 crore shares. The other two shareholders Empower Discretionary Trust and Nilay Discretionary Trust are offloading 35.73 lakhs and 18.45 lakhs shares, respectively.
The company plans to utilise the fresh issue proceeds for funding incremental working capital requirements, capital expenditure requirements and for general corporate purposes.
The previous largest IPO in pharma space was Rs 1,741 crore raised by Eris Lifesciences in 2017 while Alkem Laboratories and Laurus Labs raised about Rs 1,350 crore each in 2015 and 2016, respectively. So far in India, only 14 companies have raised over Rs 6,000 crore through IPOs.
The company which filed its draft papers in July received capital markets regulator Sebi's go-ahead last week.
Fosun Singapore which is a subsidiary of Shanghai Fosun Pharma holds 74% stake in the company. Other investors of the company include Gland Celsus which owns 12.97% while Empower Trust and Nilay Trust own 5.08% and 2.42% stake respectively.
Kotak Mahindra Capital Company, Citigroup, Haitong Securities and Nomura Financial Advisory and Securities are the book running lead managers to the IPO.
The Hyderabad based pharma company has reported Rs 2,772 crore revenue for the year ended March 2020 as against Rs 2,129.7 crore in the previous year. In 2019-20, it reported a profit of Rs 772.8 crore against a profit of Rs 451.8 crore in the previous fiscal.
So far in 2020, 11 companies have raised Rs 18,484 crore through IPOs of which SBI Cards and Payment Services alone has raised Rs 10,350 crore.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Also Read
Even before IPO details are out, Gland Pharma buzzing in grey market
Gland Pharma gets Sebi's go-ahead to float IPO
Ahead of Gland Pharma IPO, ED wants Raju family's 3.87% stake transferred to it
China’s Fosun plans D-Street debut for Gland Pharma
Gland Pharma seeks lock-in exemption for shares owned by Ex Satyam CEO Ramanlinga Raju
Chinese firm-backed Gland Pharma files for IPO; may raise up to Rs 6,000 crore
2 Comments on this Story
HYL Climbs1 hour ago Any one can buy this share at Discount after listing. Dont get trapped. | |
Harsh Visharia1 hour ago as per the grey market premium of 175-185 rupees in your previous article on price of 1300-1320 the price comes around 1475-1505 which means there is no real premium now in the grey market. offcourse we are talking about grey market nothing is official here. |